Detection Equipment and Technology Evaluation to Counter the Threat of Fentanyl and Xylazine Act of 2024

• Authority: United States Congress
• Parent authority: Federal government
• Jurisdiction: United States
• Collections: U.S. federal laws
• Most recent activity: Defunct
• Most recent activity date: 2025-01-03

Risk subdomain coverage

Minimal coverage — Brief mention but no specific mitigations, recommendations or governance measures relating to the risk subdomain are described.

• AI system security vulnerabilities
• Governance failure
• Lack of capability or robustness

All other risk subdomains had no coverage in this document.

Risk Coverage Summary

The document has minimal coverage of AI risk domains, with limited focus on AI system security (2.2) and governance (6.5). The primary focus is on drug detection equipment development rather than comprehensive AI risk management. Coverage is concentrated in technical system requirements and regulatory compliance rather than broader AI safety concerns.

Sector coverage

Good coverage — Comprehensive governance measures or mitigations with clear procedures relating to the sector are explicitly described.

• Scientific Research & Development Services
• Public Administration (excl. National Security)

Minimal coverage — Brief mention but no specific mitigations, recommendations or governance measures relating to the sector are described.

• Information
• National Security

All other sectors had no coverage in this document.

Sectors Summary

The document primarily governs the Public Administration excluding National Security sector by directing federal agencies (DHS, DEA) to develop AI-enhanced drug detection capabilities. It also has secondary coverage of Scientific Research and Development Services through mandated R&D activities, and minimal coverage of Information sector through AI/ML technology development requirements.

Legislative Status

Hard Law

Legislative Status Summary

This is a binding federal statute passed by the U.S. House of Representatives that amends the Homeland Security Act of 2002, creating mandatory legal obligations for the Under Secretary for Science and Technology with enforceable requirements.

Actors

Proposer

• Entity Types: AI_Governance_Actor
• Entities: United States House of Representatives
• Summary: The document was passed by the House of Representatives on September 9, 2024, indicating this legislative body proposed and approved the Act.

Target

• Entity Types: AI_Governance_Actor, AI_Developer
• Entities: Under Secretary for Science and Technology; Directorate of Science and Technology; Department of Homeland Security
• Summary: The Act specifically targets the Under Secretary for Science and Technology and the Directorate of Science and Technology within DHS, requiring them to conduct research and development on AI-enhanced drug detection equipment.

Enforcer

• Entity Types: AI_Governance_Actor
• Entities: Department of Homeland Security; Under Secretary for Science and Technology
• Summary: The Department of Homeland Security, through the Under Secretary for Science and Technology, has authority to implement and oversee compliance with the Act's requirements as part of the amended Homeland Security Act.

Monitor

• Entity Types: AI_Governance_Actor
• Entities: Drug Enforcement Administration; National Institute of Standards and Technology
• Summary: The DEA provides threat assessment information to guide priorities, and NIST provides the AI Risk Management Framework that must be followed, suggesting both have monitoring and guidance roles.

AI Lifecycle Stages

Lifecycle stages covered by the documents, as defined in the OECD Framework for the Classification of AI Systems

• Plan and Design
• Collect and Process Data
• Build and Use Model
• Verify and Validate
• Deploy
• Operate and Monitor

AI Lifecycle Summary

The document primarily covers the Plan and Design, Build and Use Model, and Verify and Validate stages of the AI lifecycle. It mandates research and development of AI-enhanced drug detection technologies, requires adherence to NIST AI Risk Management Framework, and emphasizes testing and evaluation of equipment effectiveness and safety.

Technical Scope

Terms relating to technical scope that are mentioned or implicitly referenced in the document

• AI Models
• AI Systems
• Predictive AI
• Task-specific AI

Technical Scope Summary

The document explicitly mentions artificial intelligence and machine learning technologies for drug detection. It references AI as defined in the National Artificial Intelligence Initiative Act and requires adherence to NIST AI Risk Management Framework. The focus is on task-specific AI applications for controlled substance detection rather than general-purpose or frontier AI systems.